Amorolfine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Amorolfine
Accession Number
DB09056
Type
Small Molecule
Groups
Approved, Investigational
Description

Amorolfine or amorolfin, is a morpholine antifungal drug that inhibits the fungal enzymes D14 reductase and D7-D8 isomerase. This inhibition affects fungal sterol synthesis pathways, depleting ergosterol and causing ignosterol to accumulate in the fungal cytoplasmic cell membranes. Amorolfine is marketed as Curanail, Loceryl, Locetar, and Odenil. It is available in the form of a 5% amorolfine nail lacquer used to treat onychomycosis (fungal infection of the toe- and fingernails). Amorolfine 5% nail lacquer in once or twice weekly applications is 60-71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment) were 38-46%. However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.

It is a topical solution for the treatment of toenail infections. Systemic treatments may be considered more effective.

It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries. It is not approved for the treatment of onychomycosis in the United States or Canada.

Structure
Thumb
Synonyms
  • Amorolfin
  • Amorolfina
  • Amorolfine
External IDs
RO 14-4767/000 / RO-14-4767/000
Product Ingredients
IngredientUNIICASInChI Key
Amorolfine hydrochloride741YH7379H78613-38-4XZKWIPVTHGWDCF-KUZYQSSXSA-N
International/Other Brands
Curanail / Loceryl / Locetar / Odenil
Categories
UNII
AB0BHP2FH0
CAS number
78613-35-1
Weight
Average: 317.517
Monoisotopic: 317.271864751
Chemical Formula
C21H35NO
InChI Key
MQHLMHIZUIDKOO-AYHJJNSGSA-N
InChI
InChI=1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16?,17-,18+
IUPAC Name
(2R,6S)-2,6-dimethyl-4-(2-{[4-(2-methylbutan-2-yl)phenyl]methyl}propyl)morpholine
SMILES
[H]C(C)(CN1C[C@]([H])(C)O[C@]([H])(C)C1)CC1=CC=C(C=C1)C(C)(C)CC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Amorolfine.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Amorolfine.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Amorolfine.
AcenocoumarolAmorolfine may increase the anticoagulant activities of Acenocoumarol.
ClorindioneThe therapeutic efficacy of Clorindione can be increased when used in combination with Amorolfine.
CoumarinThe therapeutic efficacy of Coumarin can be increased when used in combination with Amorolfine.
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Amorolfine.
DiphenadioneThe therapeutic efficacy of Diphenadione can be increased when used in combination with Amorolfine.
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Amorolfine.
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Amorolfine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
49010
RxNav
17804
ChEBI
599440
ChEMBL
CHEMBL489411
Wikipedia
Amorolfine
ATC Codes
D01AE16 — Amorolfine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentOnychomycosis1
3CompletedTreatmentOnychomycosis2
4CompletedTreatmentFoot Dermatoses3
4CompletedTreatmentOnychomycosis1
4RecruitingTreatmentNon-dermatophyte Onychomycosis1
4Unknown StatusTreatmentOnychomycosis1
Not AvailableCompletedTreatmentOnychomycosis1
Not AvailableCompletedTreatmentOnychomycosis of Toenail1
Not AvailableNot Yet RecruitingTreatmentOnychomycosis of Toenail1
Not AvailableUnknown StatusTreatmentOnycomycosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000785 mg/mLALOGPS
logP5.44ALOGPS
logP5.62ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.61 m3·mol-1ChemAxon
Polarizability40.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / Morpholines / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylpropane / Aralkylamine / Morpholine / Oxazinane / Tertiary amine / Tertiary aliphatic amine / Organoheterocyclic compound / Ether / Dialkyl ether / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, morpholine antifungal drug (CHEBI:599440)

Drug created on May 11, 2015 12:00 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates